Small Cancer Therapy Player Celularity To Provide Research Support For Regeneron's Therapy

Celularity Inc CELU shares are trading higher after the company announced a multi-year Research Collaboration Services Agreement with Regeneron Pharmaceuticals Inc REGN.

The pact supports the research of Regeneron's allogeneic cell therapy candidates.

The agreement will initially focus on researching a targeted allogeneic gamma delta chimeric antigen receptor (CAR) T-cell therapy owned by Regeneron designed to enhance proliferation and potency against solid tumors. 

The research will occur at Celularity's facility in Florham Park, N.J. 

Financial terms were not disclosed.

The company says the agreement underscores Celularity's demonstrated expertise in cell therapy research.

Celularity is a biotechnology company focused on cellular and regenerative medicine by developing allogeneic cryopreserved off-the-shelf placental-derived cell therapies.

Price Action: CELU shares are up 4.55% at $0.30 on the last check Tuesday.